Last reviewed · How we verify

NCT06821919: NETs

Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)

Recruiting now Last updated 12 February 2025
What this trial tests

trial in Diabetes Mellitus in 70 participants. Currently enrolling.

Timeline
13 May 2024
Primary endpoint
30 December 2030
30 December 2031

Quick facts

Lead sponsorWestern Galilee Hospital-Nahariya
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment70
Start date13 May 2024
Primary completion30 December 2030
Estimated completion30 December 2031
Sites1 location across Israel

Conditions studied

Sponsor

Western Galilee Hospital-Nahariya

Who can join

18 and older, any sex, with Diabetes Mellitus or Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate whether new glucose-lowering medications, such as SGLT2 inhibitors (e.g., Forxiga/Jardiance) and GLP-1 receptor agonists (e.g., Ozempic), can reduce NETosis in diabetic patients, thereby mitigating secondary complications such as cardiovascular disease and kidney damage. By targeting dysregulated NET formation, the study seeks to establish a link between reduced NETosis and improved clinical outcomes in diabetes. Additionally, the study will evaluate the effects of immunosuppressive therapies on NETosis in patients with immune-mediated kidney diseases, such as ANCA-associated vasculitis. By correlating NETosis activity with disease progression and treatment response, this research will assess whether reducing NETosis contributes to better management of inflammation and secondary morbidity in these conditions. Through these evaluations, the study aims to identify potential therapeutic strategies to improve outcomes in both diabetic and chronic kidney disease populations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other Western Galilee Hospital-Nahariya trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06821919.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing